名臣健康(002919) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥406,772,539.06, representing a 172.98% increase compared to ¥149,012,185.35 in the same period last year[5] - Net profit attributable to shareholders was ¥34,104,153.62, up 1,981.81% from ¥1,638,200.89 in Q1 2022[5] - The net profit after deducting non-recurring gains and losses was ¥33,521,743.74, a 2,385.64% increase from ¥1,348,618.09 in the previous year[5] - The company's basic and diluted earnings per share both increased to ¥0.20, a 1,900.00% rise from ¥0.01 in Q1 2022[5] - Operating profit for the quarter was ¥24,659,339.14, compared to just ¥1,050,322.55 in Q1 2022, indicating a substantial improvement in profitability[22] - Net profit attributable to the parent company was ¥34,104,153.62, a remarkable increase from ¥1,638,200.89 in the previous year, reflecting a year-over-year growth of over 1965%[22] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,264,401,026.81, a 1.72% increase from ¥1,243,033,194.99 at the end of the previous year[5] - The company's total assets as of March 31, 2023, amount to CNY 1,264,401,026.81, an increase from CNY 1,243,033,194.99 at the beginning of the year[18] - Total current assets are reported at CNY 677,626,885.64, compared to CNY 638,873,323.41 at the beginning of the year, reflecting an increase of approximately 6.0%[17] - Total non-current assets decreased to CNY 586,774,141.17 from CNY 604,159,871.58, a decline of about 2.0%[18] - Total liabilities amount to CNY 491,048,992.65, down from CNY 503,785,314.45, indicating a reduction of approximately 2.5%[18] - The total equity remains stable at CNY 773,352,033.16, unchanged from the previous reporting period[18] Cash Flow - Cash flow from operating activities improved to -¥59,671,619.97, a 15.36% improvement compared to -¥70,501,835.42 in Q1 2022[13] - The cash inflow from operating activities totaled ¥399,260,552.94, compared to ¥165,458,573.09 in the same period last year, indicating improved cash generation capabilities[23] - The net cash flow from investing activities was -2,100,092.89, compared to -65,252,988.05 in the previous period[25] - The total cash outflow from financing activities was 4,657,413.14, with a net cash flow from financing activities of -4,657,413.14, down from -1,065,710.00 previously[25] - The net increase in cash and cash equivalents was -66,429,126.00, compared to -136,820,533.47 in the prior period[25] - The ending balance of cash and cash equivalents was 68,987,820.59, down from 114,077,895.54 in the previous period[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 5,977[14] - The largest shareholder, Chen Qinfang, holds 37.00% of the shares, totaling 63,270,900 shares[14] Expenses - Sales expenses surged by 896.91% to ¥159,736,843.38, driven by higher promotional expenditures related to the growth of the gaming business[12] - Research and development expenses increased to ¥31,582,395.46 from ¥24,383,528.86, indicating a focus on innovation and product development[21] - The company reported a total operating cost of ¥379,638,664.04, which is significantly higher than ¥142,910,650.51 from the previous year, primarily driven by increased sales expenses[21] Other Income - The company reported a significant increase in other income, which rose by 144.78% to ¥743,157.00, attributed to increased input tax deductions[12] Return on Equity - The weighted average return on equity improved to 4.51%, up from 0.22% in the same period last year[5] Inventory - The company's inventory increased to CNY 208,640,338.46 from CNY 191,289,119.65, reflecting an increase of about 9.1%[17] Audit Status - The company’s first-quarter report was not audited[26]